View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Stereotaxis, Inc.
Entity Filer Category	Smaller Reporting Company
Entity Central Index Key	0001289340
Trading Symbol	stxs
Amendment Flag	false
Document Type	10-Q
Document Fiscal Period Focus	Q1
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		21,758,330

Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 1,602,951	$ 5,593,582
Accounts receivable, net of allowance of $155,964 and $93,478 in 2016 and 2015, respectively	6,397,660	6,376,470
Inventories	4,446,363	4,504,282
Prepaid expenses and other current assets	1,150,631	668,659
Total current assets	13,597,605	17,142,993
Property and equipment, net	969,927	1,067,321
Intangible assets, net	586,059	635,889
Other assets	32,341	31,693
Total assets	15,185,932	18,877,896
Current liabilities:
Accounts payable	2,042,246	1,840,135
Accrued liabilities	5,245,395	6,058,390
Deferred revenue	6,627,020	7,445,935
Warrants and debt conversion features	762,836	794,130
Total current liabilities	14,677,497	16,138,590
Long-term debt	18,078,308	18,080,159
Long-term deferred revenue	1,782,155	2,009,198
Other liabilities	270,433	275,603
Total liabilities	34,808,393	36,503,550
Stockholders' deficit:
Preferred stock, par value $0.001; 10,000,000 shares authorized, none outstanding at 2016 and 2015
Common stock, par value $0.001; 300,000,000 shares authorized, 21,738,923 and 21,551,173 shares issued at 2016 and 2015, respectively	21,739	21,551
Additional paid in capital	448,794,778	448,517,472
Treasury stock, 4,015 shares at 2016 and 2015	(205,999)	(205,999)
Accumulated deficit	(468,232,979)	(465,958,678)
Total stockholders' deficit	(19,622,461)	(17,625,654)
Total liabilities and stockholders' deficit	$ 15,185,932	$ 18,877,896

Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Accounts receivable, allowance	$ 155,964	$ 93,478
Stockholders' deficit:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	21,738,923	21,551,173
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	3 Months Ended
Statements Of Operations - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Revenue:
Systems	$ 2,075,019	$ 2,831,178
Disposables, service and accessories	6,572,987	6,699,848
Total revenue	8,648,006	9,531,026
Cost of revenue:
Systems	1,083,099	1,400,267
Disposables, service and accessories	1,097,715	1,230,370
Total cost of revenue	2,180,814	2,630,637
Gross margin	6,467,192	6,900,389
Operating expenses:
Research and development	1,473,086	1,485,706
Sales and marketing	3,894,113	4,034,371
General and administrative	2,586,791	2,794,590
Total operating expenses	7,953,990	8,314,667
Operating loss	(1,486,798)	(1,414,278)
Other income (expense)	31,294	(892,377)
Interest income	222	862
Interest expense	(819,019)	(829,788)
Net loss	$ (2,274,301)	$ (3,135,581)
Net loss per common share:
Basic	$ (0.11)	$ (0.15)
Diluted	$ (0.11)	$ (0.15)
Weighted average shares used in computing net loss per common share:
Basic	21,611,612	20,742,932
Diluted	21,611,612	20,742,932

Statements Of Cash Flows - USD ($)	3 Months Ended
Statements Of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (2,274,301)	$ (3,135,581)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	97,394	70,256
Amortization of intangibles	49,830	74,959
Amortization of deferred finance costs	54,937	55,793
Share-based compensation	270,102	326,444
Adjustment of warrants	(31,294)	892,377
Changes in operating assets and liabilities:
Accounts receivable	(21,190)	(1,256,119)
Inventories	57,919	(4,179)
Prepaid expenses and other current assets	(407,930)	92,225
Other assets	(648)	35,983
Accounts payable	202,111	250,495
Accrued liabilities	(812,995)	(263,221)
Deferred revenue	(1,045,958)	(352,450)
Other liabilities	(5,170)	(75,682)
Net cash used in operating activities	(3,867,193)	(3,288,700)
Cash flows from investing activities
Purchase of equipment		(52,410)
Net cash used in investing activities		(52,410)
Cash flows from financing activities
Payments of deferred financing costs	(100,000)
Proceeds from (payments to) Healthcare Royalty Partners debt	(30,830)	(68,869)
Proceeds from issuance of stock, net of issuance costs	7,392	578,211
Net cash provided by (used in) financing activities	(123,438)	509,342
Net increase (decrease) in cash and cash equivalents	(3,990,631)	(2,831,768)
Cash and cash equivalents at beginning of period	5,593,582	7,270,301
Cash and cash equivalents at end of period	$ 1,602,951	$ 4,438,533

Description Of Business	3 Months Ended
Description Of Business	Mar. 31, 2016
Description Of Business [Abstract]
Description Of Business	1. Description of Business Stereotaxis designs, manufactures, and markets the Epoch® Solution, an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency, and efficacy for catheter-based or interventional procedures. The Epoch Solution is comprised of the Niobe® ES Magnetic Navigation System (“Niobe ES system”), Odyssey® Information Management Solution (“Odyssey Solution”), and the Vdrive® Robotic Navigation System (“Vdrive system”) and related devices. The Niobe ES system is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures, and reduced X-ray exposure. In addition to the Niobe ES system and its components, Stereotaxis has also developed the Odyssey Solution, which consolidates all lab information, enabling doctors to focus on the patient for optimal procedure efficiency. The platform also features a remote viewing and recording capability called the Odyssey Cinema™ system, an innovative system delivering synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital’s local area network and over the global Odyssey Network, providing physicians with a tool for clinical collaboration, remote consultation, and training. Our Vdrive system provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive system complements the Niobe ES system’s control of therapeutic catheters for fully remote procedures and enables single-operator workflow. It is sold as two options, the Vdrive system and the Vdrive Duo™ system. In addition to the Vdrive system and the Vdrive Duo system, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond the warranty period, and software licenses. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion may be implemented upon purchase of the necessary components. As of March 31, 2016, the Company has an installed base of 126 Niobe ES systems. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan and various other countries. We have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Vdrive and Vdrive Duo systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and European Union. We have received Food and Drug Administration (“FDA”) clearance and the CE Mark necessary for us to market our suite of Pegasus™ coronary peripheral guidewires in the United States and Europe. Since our inception, we have generated significant losses. As of March 31, 2016, we incurred cumulative net losses of approximately $468.2 million. In 2016, the Company plans to continue developing the Niobe ES system with the goal of furthering clinical adoption and new system placements. We expect to incur additional losses into 2016 as we continue the development and commercialization of our products, conduct our research and development activities and advance new products into clinical development from our existing research programs and fund additional sales and marketing initiatives. During 2016, we will continue to monitor operating expenses and make additional investment in certain targeted areas. We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities, and loans collateralized by working capital and equipment. We continue to explore financing alternatives, which may include the sale of equity securities or non-core assets, strategic collaboration agreements, debt financings, or distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control. Our existing cash, cash equivalents, and borrowing facilities may not be sufficient to fund our operating expenses and capital equipment requirements through the next 12 months, which would require us to obtain additional financing. We may be required to raise capital or pursue other financing strategies to continue our operations. Until we can generate significant cash flow from our operations, we expect to continue to fund our operations with cash resources primarily generated from the proceeds of our past and future public offerings, private sales of our equity securities, and loans collateralized by working capital and equipment. We continue to explore financing alternatives, which may include the sale of equity securities or non-core assets, strategic collaboration agreements, debt financings, or distribution rights. We cannot accurately predict the timing and amount of our utilization of capital, which will depend on a number of factors outside of our control. We cannot assure that additional financing will be available on acceptable terms or that such financing will not be dilutive to our stockholders. If adequate funds are not available to us, we could be required to delay development or commercialization of new products, to license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize ourselves, or to reduce the sales, marketing, customer support or other resources devoted to our products, any of which could have a material adverse effect on our business, financial condition, and operational results. In addition, we could be required to cease operations.

Summary Of Significant Accounting Policies

3 Months Ended

Mar. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the three month period ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016 or for future operating periods.

These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission (SEC) on March 11, 2016.

Financial Instruments

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value. See Note 9 for disclosure of the fair value of debt.

The Company measures certain financial assets and liabilities, including warrants, at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.

Revenue and Costs of Revenue

The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”).

ASC 605-25 permits management to estimate the selling price of undelivered components of a bundled sale for which it is unable to establish vendor-specific objective evidence (“VSOE”) or third-party evidence (“TPE”). This requires management to record revenue for certain elements of a transaction even though it might not have delivered other elements of the transaction, for which it was unable to meet the requirements for establishing VSOE or TPE. The Company believes that the guidance significantly improves the reporting of these types of transactions to more closely reflect the underlying economic circumstances. This guidance also prohibits the use of the residual method for allocating revenue to the various elements of a transaction and requires that the revenue be allocated proportionally based on the relative estimated selling prices.

Under our revenue recognition policy, a portion of revenue for Niobe systems, Vdrive systems and certain Odyssey systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue. Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimis effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Share-Based Compensation

The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.

The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Net Earnings (Loss) per Common Share (“EPS”)

Basic and diluted net earnings (loss) per common share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period.

The following table sets forth the computation of basic and diluted EPS:


		Three months ended March 31,
Numerator:		2016		2015
Numerator for basic EPS	$	(2,274,301)	$	(3,135,581)
Numerator for diluted EPS	$	(2,274,301)	$	(3,135,581)
Denominator:
Denominator for basic EPS—weighted average shares		21,611,612		20,742,932
Denominator for diluted EPS—weighted average shares		21,611,612		20,742,932
Basic EPS	$	(0.11)	$	(0.15)
Diluted EPS	$	(0.11)	$	(0.15)

In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.

As of March 31, 2016, the Company had 695,117 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $9.32 per share, 2,040,365 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $3.44 per share, and 1,271,276 shares of unvested restricted share units.

Recently Issued Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU” or “Update”) No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting”. This amendment is intended to simplify several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, forfeitures, and classification on the statement of cash flows. This update is effective for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company) and interim periods within those fiscal years, with earlier application permitted. The Company is evaluating the impact of this guidance on its financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-02, “Leases (ASC 842)”, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard requires lessors to account for leases using an approach that is substantially equivalent to existing guidance for sales-type leases, direct financing leases and operating leases. ASC 842 supersedes the previous leases standard, ASC 840 Leases. The standard is effective for interim and annual periods beginning after December 31, 2018 (January 1, 2019 for the Company), with early adoption permitted. The Company is in the process of evaluating the impact of this accounting standard update.

In November 2015, the FASB issued ASU No. 2015-17, “Income Taxes (Topic 740): To simplify the presentation of deferred income taxes”. The amendments in this Update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments in this Update apply to all entities that present a classified statement of financial position. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by the amendments in this Update. This standard is effective for public companies for financial statements issued for annual periods beginning after December 15, 2016 (January 1, 2017 for the Company), and interim periods within those annual periods. We adopted this accounting standard update in 2015 and there was no impact to the results of operations or cash flows.

In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” regarding the subsequent measurement of inventory as part of its Simplification Initiative. This standard is effective for public companies for fiscal years beginning after December 15, 2016 (January 1, 2017 for the Company), including interim periods within those fiscal years. This Update should be applied prospectively, and early application is permitted as of the beginning of an interim or annual reporting period. We are currently evaluating the impact of adopting this accounting standard update but do not expect this to significantly impact the results of operations, financial conditions, cash flows, or financial statement presentation.

In April 2015, the FASB issued ASU No. 2015-03, “Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs”. To simplify the presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from that debt liability, consistent with the presentation of a debt discount. In August 2015, the FASB issued ASU 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements—Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting (SEC Update), which adds the SEC staff’s guidance on the presentation of debt issuance costs associated with lines of credit to the Codification. The SEC staff stated it will not object to an entity presenting the costs of securing line-of-credit arrangements as an asset, regardless of whether there are any outstanding borrowings. The Standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 (January 1, 2016 for the Company), and interim periods within those fiscal years. Early adoption of the amendments in this Update is permitted for financial statements that have not been previously issued. We have adopted this accounting standard update. The Company’s balance sheets as of March 31, 2016 and December 31, 2015 included $320,039 and $349,018, respectively, of deferred financing costs (excluding $100,000 and $25,960, respectively, related to line-of-credit arrangements) that were, under the new guidance, presented as a direct reduction to debt liabilities.

In August 2014, the FASB issued ASU No. 2014-15, to communicate amendments to FASB Account Standards Codification Subtopic 205-40, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. The ASU requires management to evaluate relevant conditions, events and certain management plans that are known or reasonably knowable as of the evaluation date when determining whether substantial doubt about an entity’s ability to continue as a going concern exists. Management will be required to make this evaluation for both annual and interim reporting periods. Management will have to make certain disclosures if it concludes that substantial doubt exists and when it plans to alleviate substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for annual periods ending after December 15, 2016 and for interim reporting periods starting in the first quarter of 2017 (December 31, 2016 for the Company). Early adoption is permitted. We are currently evaluating the impact of adopting this accounting standard update on our financial statement disclosures.

In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers" which converges the FASB's and the International Accounting Standards Board's current standards on revenue recognition. The standard provides companies with a single model to use in accounting for revenue arising from contracts with customers and supersedes current revenue guidance. The standard is effective for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The standard permits companies to either apply the adoption to all periods presented, or apply the requirements in the year of adoption through a cumulative adjustment. In April 2015, the FASB issued an exposure draft related to the deferral of the effective date, which would delay our effective date one year. Therefore, the standard would be effective for annual and interim periods beginning after December 15, 2017 (January 1, 2018 for the Company). We are currently evaluating the impact of adopting this accounting standard update on our financial statements and disclosures and have not concluded on an adoption method.

Inventories

3 Months Ended

Mar. 31, 2016

Inventories [Abstract]

Inventories

3. Inventories

Inventories consist of the following:


	March 31, 2016	December 31, 2015

Raw materials	$ 2,354,810	$ 2,065,676
Work in process	427,952	24,758
Finished goods	1,702,100	2,433,819
Reserve for obsolescence	(38,499)	(19,971)
Total inventory	$ 4,446,363	$ 4,504,282

Prepaid Expenses And Other Current Assets

3 Months Ended

Mar. 31, 2016

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:



	March 31, 2016	December 31, 2015

Prepaid expenses	$ 675,820	$ 454,822
Deferred financing costs	100,000	25,960
Deposits	312,713	136,583
Deferred cost of revenue	94,439	82,987
Total prepaid expenses and other assets	1,182,972	700,352
Less: Noncurrent prepaid expenses and other assets	(32,341)	(31,693)
Total current prepaid expenses and other assets	$ 1,150,631	$ 668,659

Certain prior year amounts have been reclassified to conform to the 2016 presentation.

Property And Equipment

3 Months Ended

Mar. 31, 2016

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	March 31,	December 31,
	2016	2015

Equipment	$ 8,496,636	$ 8,496,636
Equipment held for lease	303,412	303,412
Leasehold improvements	2,320,368	2,320,368
	11,120,416	11,120,416
Less: Accumulated depreciation	(10,150,489)	(10,053,095)
Net property and equipment	$ 969,927	$ 1,067,321

Intangible Assets	3 Months Ended
Intangible Assets	Mar. 31, 2016
Intangible Assets [Abstract]
Intangible Assets	6. Intangible Assets As of March 31, 2016, the Company had total intangible assets of $3,221,069. Accumulated amortization at March 31, 2016, was $2,635,010.

Accrued Liabilities

3 Months Ended

Mar. 31, 2016

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	March 31,	December 31,
	2016	2015

Accrued salaries, bonus, and benefits	$ 2,266,158	$ 3,053,012
Accrued rent	1,263,383	1,361,379
Accrued licenses and maintenance fees	660,781	666,373
Accrued interest	493,876	494,703
Accrued warranties	302,362	316,835
Accrued taxes	335,102	324,226
Other	194,166	117,465
Total accrued liabilities	5,515,828	6,333,993
Less: Long term accrued liabilities	(270,433)	(275,603)
Total current accrued liabilities	$ 5,245,395	$ 6,058,390

Our primary company facilities are located in St. Louis, Missouri where we currently lease approximately 52,000 square feet of office and 12,000 square feet of demonstration and assembly space. In the third quarter of 2013, the Company modified the existing lease agreement to terminate approximately 13,000 square feet of unimproved space. The costs associated with the termination were $515,138 and were accrued as a rent liability as of September 30, 2013. As of March 31, 2016, the remaining accrued costs associated with the termination were $258,995.

In the fourth quarter of 2015, the Company entered a sublease agreement to sublease 3,152 square feet of the first floor office space through December 31, 2018.

Deferred Revenue

3 Months Ended

Mar. 31, 2016

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	March 31,	December 31,
	2016	2015

Product shipped, revenue deferred	$ 455,314	$ 366,388
Customer deposits	1,050,000	2,505,000
Deferred service and license fees	6,903,861	6,583,745
Total deferred revenue	8,409,175	9,455,133
Less: Long-term deferred revenue	(1,782,155)	(2,009,198)
Total current deferred revenue	$ 6,627,020	$ 7,445,935

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities

3 Months Ended

Mar. 31, 2016

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:


	March 31, 2016		December 31, 2015
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ 18,078,308	$ 18,398,347	$ 18,080,159	$ 18,429,177
Less current maturities	—	—	—	—
Total long term debt	$ 18,078,308	$ 18,398,347	$ 18,080,159	$ 18,429,177

In accordance with general accounting principles for fair value measurement, the Company’s debt and credit facilities were measured at fair value as of March 31, 2016 and December 31, 2015. Long-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value (Level 3).

Certain prior year amounts have been reclassified to conform to the 2016 presentation.

Revolving Line of Credit

The Company has had a working capital line of credit with its primary lender, Silicon Valley Bank, since 2004. The revolving line of credit is secured by substantially all of the Company’s assets. The maximum available under the line is $10 million subject to the value of collateralized assets. The Company is required under the revolving line of credit to maintain its primary operating account and the majority of its cash and investment balances in accounts with its primary lender. The facility was amended on March 27, 2015, extending the maturity date to March 31, 2018 and on May 10, 2016, the Company and the primary lender agreed to modify certain financial covenants. The amended agreement requires the Company to maintain a liquidity ratio greater than 1.50:1.00, excluding certain short term advances from the calculation, and a minimum tangible net worth of not less than (no worse than) negative $24.0 million for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24.5 million for the quarters ended December 31, 2017 and March 31, 2018.

As of March 31, 2016, the Company had no outstanding debt under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of March 31, 2016, the Company had a borrowing capacity of $4.9 million based on the Company’s collateralized assets, and cash and cash equivalents of $1.6 million for a total liquidity of $6.5 million.

Healthcare Royalty Partners Debt

In November 2011, the Company entered into a loan agreement with Healthcare Royalty Partners. Under the agreement the Company borrowed from Healthcare Royalty Partners $15 million. The Company was permitted to borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe ES system sales in 2012. On August 8, 2012, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the three months ended June 30, 2012. On January 31, 2013, the Company borrowed an additional $2.5 million based upon achievement of a milestone related to Niobe ES system sales for the twelve months ended December 31, 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. (the “Biosense Agreement”). The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe ES system in cardiac ablation procedures. Under the terms of the agreement, Healthcare Royalty Partners will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender.

Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Stockholders' Equity

10. Stockholders’ Equity

The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the prior rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement. Since the Company’s inception, no dividends have been declared or paid.

Controlled Equity Offering

The Company entered into a Controlled Equity OfferingSM sales agreement (the “Sales Agreement”) in May 2014, as amended on March 26, 2015, with Cantor Fitzgerald & Co. (“Cantor”), as agent and/or principal, pursuant to which the Company could issue and sell, from time to time, shares of its common stock having an aggregate gross sales price of up to $18.0 million. The Company will pay Cantor a commission of 3.0% of the gross proceeds from any common stock sold through the Sales Agreement.

There were no proceeds from the Controlled Equity Offering during the three months ended March 31, 2016. As of March 31, 2016, $13.8 million of common stock remained available to be sold under this facility, subject to certain conditions as specified in the Sales Agreement.

Offerings of Common Stock

On October 8, 2015 the Company announced the results of its previously announced offering of transferable subscription warrants (the “Warrants Offering) to holders of record of the Company’s common stock. Pursuant to the Warrants Offering, subscription warrants to purchase 267,256 shares of common stock were exercised, resulting in gross proceeds to the Company of $293,982.

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In August 2012, the Board of Directors adopted the 2012 Stock Incentive Plan (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012.

On June 5, 2013 and on June 10, 2014, the shareholders approved amendments to the Plan, which were previously approved and adopted by the Compensation Committee of the Board of Directors of the Company. Each of these amendments increased the number of shares authorized for issuance under the Plan by one million shares. At March 31, 2016, the Company had 46,051 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans.

At March 31, 2016, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $2.3 million, net of estimated forfeitures of approximately $0.7 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods.

A summary of the option and stock appreciation rights activity for the three month period ended March 31, 2016 is as follows:


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2015	706,494	$1.45 - $116.40	$9.34
Granted	-	-	-
Exercised	-	-	-
Forfeited	(11,377)	$1.74 - $36.20	$9.98
Outstanding, March 31, 2016	695,117	$1.45 - $116.40	$9.32

A summary of the restricted stock unit activity for the three month period ended March 31, 2016 is as follows:


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2015	752,008	$2.63
Granted	700,600	$0.78
Vested	(175,100)	$3.00
Forfeited	(6,232)	$2.73
Outstanding, March 31, 2016	1,271,276	$1.56

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Fair Value Measurements

3 Months Ended

Mar. 31, 2016

Fair Value Measurements [Abstract]

Fair Value Measurements

11. Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). The three levels of the fair value hierarchy are described below:

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at March 31, 2016:
Cash equivalents	$	347,821	347,821	—	—
Total assets at fair value	$	347,821	347,821	—	—
Liabilities at March 31, 2016:
Warrants issued May 2012	$	237,650	—	—	237,650
Warrants issued August 2013	$	525,186	—	—	525,186
Total liabilities at fair value:	$	762,836	—	—	762,836
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 2012	$	143,681	—	—	143,681
Warrants issued August 2013	$	650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $347,821 and $524,083 at March 31, 2016 and December 31, 2015, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the three month periods ended March 31, 2016, and March 31, 2015. There were no transfers in or out of Level 1 during the period ended March 31, 2016.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with the Company’s May 2012 and August 2013 financing transactions, the Company issued warrants to purchase shares of the Company’s common stock. Due to the provisions included in the warrant agreements, the warrants did not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically re-measured with any changes in value recognized in “Other expense” in the Statements of Operations.

The remaining warrants from the May 2012 transaction expire in May 2018 and were revalued as of March 31, 2016 using the following assumptions: 1) volatility of 113.14%; 2) risk-free interest rate of 0.73%; and 3) a closing stock price of $1.10.

The remaining warrants from the August 2013 expire in November 2018 and were revalued as of March 31, 2016 using the following assumptions: 1) volatility of 110.74%; 2) risk-free interest rate of 0.87%; and 3) a closing stock price of $1.10.

The significant unobservable input used in the fair value measurement of the Company’s warrants is volatility. Significant increases (decreases) in the volatility in isolation would result in significantly higher (lower) liability fair value measurements.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three month period ended March 31, 2016:


	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
Balance at beginning of period	$ 143,681	$ 650,449	$ 794,130
Issues	-	-	-
Settlements	-	-	-
Revaluation	93,969	(125,263)	(31,294)
Balance at end of period	$ 237,650	$ 525,186	$ 762,836

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Product Warranty Provisions

3 Months Ended

Mar. 31, 2016

Product Warranty Provisions [Abstract]

Product Warranty Provisions

12. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe, Odyssey, and Vdrive systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	March 31, 2016		December 31, 2015
Warranty accrual, beginning of the fiscal period	$	316,835	$	364,548
Accrual adjustment for product warranty		55,262		171,384
Payments made		(69,735)		(219,097)
Warranty accrual, end of the fiscal period	$	302,362	$	316,835

Commitments And Contingencies	3 Months Ended
Commitments And Contingencies	Mar. 31, 2016
Commitments And Contingencies [Abstract]
Commitments And Contingencies	13. Commitments and Contingencies The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On May 2, 2016, Stereotaxis, Inc. (the “Company”) received a determination letter from the Nasdaq Hearings Panel (the “Panel”) granting the Company’s request for the continued listing of its common stock on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to, among other things, the Company evidencing compliance with the minimum $35 million market value of listed securities requirement (the “Market Cap Requirement”) by August 1, 2016. To satisfy the Market Cap Requirement, the Company must evidence a market value of listed securities of at least $35 million for a minimum of ten consecutive business days on or before August 1, 2016. The Company is taking definitive steps to timely comply with the terms of the Panel’s decision; however, there can be no assurance that it will be able to do so. On May 10, 2016, Stereotaxis, Inc. (the “Company”) entered into an Eleventh Loan Modification Agreement (Domestic) with Silicon Valley Bank (the “Bank”) (“Modification Agreement”), further amending the terms of that certain Second Amended and Restated Loan and Security Agreement (Domestic) dated November 30, 2011, as amended (the “Amended Loan Agreement”), to modify the financial covenants under the Amended Loan Agreement by revising the tangible net worth covenant to require the Company to maintain a minimum tangible net worth of not less than (no worse than) negative $24,000,000 for the quarters ended June 30, 2016, September 30, 2016, December 31, 2016, March 31, 2017, June 30, 2017, and September 30, 2017; and not less than (no worse than) negative $24,500,000 for the quarters ended December 31, 2017 and March 31, 2018.

Summary Of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Basis Of Presentation

Basis of Presentation

Financial Instruments

Revenue And Costs Of Revenue

Revenue and Costs of Revenue

The Company accounts for revenue using Accounting Standards Codification Topic 605-25, Multiple-Element Arrangements (“ASC 605-25”).

Share-Based Compensation

Net Earnings (Loss) Per Common Share ("EPS")

Net Earnings (Loss) per Common Share (“EPS”)

Basic and diluted net earnings (loss) per common share are computed by dividing the net income (loss) for the period by the weighted average number of common shares outstanding during the period.

The following table sets forth the computation of basic and diluted EPS:


		Three months ended March 31,
Numerator:		2016		2015
Numerator for basic EPS	$	(2,274,301)	$	(3,135,581)
Numerator for diluted EPS	$	(2,274,301)	$	(3,135,581)
Denominator:
Denominator for basic EPS—weighted average shares		21,611,612		20,742,932
Denominator for diluted EPS—weighted average shares		21,611,612		20,742,932
Basic EPS	$	(0.11)	$	(0.15)
Diluted EPS	$	(0.11)	$	(0.15)

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2016

Summary Of Significant Accounting Policies [Abstract]

Computation Of Basic And Diluted EPS


		Three months ended March 31,
Numerator:		2016		2015
Numerator for basic EPS	$	(2,274,301)	$	(3,135,581)
Numerator for diluted EPS	$	(2,274,301)	$	(3,135,581)
Denominator:
Denominator for basic EPS—weighted average shares		21,611,612		20,742,932
Denominator for diluted EPS—weighted average shares		21,611,612		20,742,932
Basic EPS	$	(0.11)	$	(0.15)
Diluted EPS	$	(0.11)	$	(0.15)

Inventories (Tables)

3 Months Ended

Mar. 31, 2016

Inventories [Abstract]

Schedule Of Inventories


	March 31, 2016	December 31, 2015

Raw materials	$ 2,354,810	$ 2,065,676
Work in process	427,952	24,758
Finished goods	1,702,100	2,433,819
Reserve for obsolescence	(38,499)	(19,971)
Total inventory	$ 4,446,363	$ 4,504,282

Prepaid Expenses And Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2016

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets



	March 31, 2016	December 31, 2015

Prepaid expenses	$ 675,820	$ 454,822
Deferred financing costs	100,000	25,960
Deposits	312,713	136,583
Deferred cost of revenue	94,439	82,987
Total prepaid expenses and other assets	1,182,972	700,352
Less: Noncurrent prepaid expenses and other assets	(32,341)	(31,693)
Total current prepaid expenses and other assets	$ 1,150,631	$ 668,659

Property And Equipment (Tables)

3 Months Ended

Mar. 31, 2016

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	March 31,	December 31,
	2016	2015

Equipment	$ 8,496,636	$ 8,496,636
Equipment held for lease	303,412	303,412
Leasehold improvements	2,320,368	2,320,368
	11,120,416	11,120,416
Less: Accumulated depreciation	(10,150,489)	(10,053,095)
Net property and equipment	$ 969,927	$ 1,067,321

Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2016

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	March 31,	December 31,
	2016	2015

Accrued salaries, bonus, and benefits	$ 2,266,158	$ 3,053,012
Accrued rent	1,263,383	1,361,379
Accrued licenses and maintenance fees	660,781	666,373
Accrued interest	493,876	494,703
Accrued warranties	302,362	316,835
Accrued taxes	335,102	324,226
Other	194,166	117,465
Total accrued liabilities	5,515,828	6,333,993
Less: Long term accrued liabilities	(270,433)	(275,603)
Total current accrued liabilities	$ 5,245,395	$ 6,058,390

Deferred Revenue (Tables)

3 Months Ended

Mar. 31, 2016

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	March 31,	December 31,
	2016	2015

Product shipped, revenue deferred	$ 455,314	$ 366,388
Customer deposits	1,050,000	2,505,000
Deferred service and license fees	6,903,861	6,583,745
Total deferred revenue	8,409,175	9,455,133
Less: Long-term deferred revenue	(1,782,155)	(2,009,198)
Total current deferred revenue	$ 6,627,020	$ 7,445,935

Long-Term Debt And Credit Facilities (Tables)

3 Months Ended

Mar. 31, 2016

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Debt Outstanding


	March 31, 2016		December 31, 2015
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Healthcare Royalty Partners debt	$ 18,078,308	$ 18,398,347	$ 18,080,159	$ 18,429,177
Less current maturities	—	—	—	—
Total long term debt	$ 18,078,308	$ 18,398,347	$ 18,080,159	$ 18,429,177

Stockholder's Equity (Tables)

3 Months Ended

Mar. 31, 2016

Stockholders' Equity [Abstract]

Summary Of Option And Stock Appreciation Rights Activity


	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2015	706,494	$1.45 - $116.40	$9.34
Granted	-	-	-
Exercised	-	-	-
Forfeited	(11,377)	$1.74 - $36.20	$9.98
Outstanding, March 31, 2016	695,117	$1.45 - $116.40	$9.32

Summary Of Restricted Stock Unit Activity


	Number of Restricted Stock Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2015	752,008	$2.63
Granted	700,600	$0.78
Vested	(175,100)	$3.00
Forfeited	(6,232)	$2.73
Outstanding, March 31, 2016	1,271,276	$1.56

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Measurements [Abstract]

Assets And Liabilities Measured At Fair Value On Recurring Basis By Level


	Fair Value Measurement Using
	Total		Quoted Prices in Active Markets for Identical Instruments (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets at March 31, 2016:
Cash equivalents	$	347,821	347,821	—	—
Total assets at fair value	$	347,821	347,821	—	—
Liabilities at March 31, 2016:
Warrants issued May 2012	$	237,650	—	—	237,650
Warrants issued August 2013	$	525,186	—	—	525,186
Total liabilities at fair value:	$	762,836	—	—	762,836
Assets at December 31, 2015:
Cash equivalents	$	524,083	524,083	—	—
Total assets at fair value	$	524,083	524,083	—	—
Liabilities at December 31, 2015:
Warrants issued May 2012	$	143,681	—	—	143,681
Warrants issued August 2013	$	650,449	—	—	650,449
Total liabilities at fair value:	$	794,130	—	—	794,130

Summary Of Changes In Fair Value Of Level 3 Financial Liabilities


	Warrants issued May 2012	Warrants issued August 2013	Total Liabilities
Balance at beginning of period	$ 143,681	$ 650,449	$ 794,130
Issues	-	-	-
Settlements	-	-	-
Revaluation	93,969	(125,263)	(31,294)
Balance at end of period	$ 237,650	$ 525,186	$ 762,836

Product Warranty Provisions (Tables)

3 Months Ended

Mar. 31, 2016

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	March 31, 2016		December 31, 2015
Warranty accrual, beginning of the fiscal period	$	316,835	$	364,548
Accrual adjustment for product warranty		55,262		171,384
Payments made		(69,735)		(219,097)
Warranty accrual, end of the fiscal period	$	302,362	$	316,835

Description Of Business (Details)	Mar. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)
Description Of Business [Abstract]
Installed base \| item	126
Cumulative net losses \| $	$ (468,232,979)	$ (465,958,678)

Summary Of Significant Accounting Policies (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Accounting Policies [Line Items]
Share-based compensation, requisite service period	4 years
Options and stock appreciation rights outstanding	695,117	706,494
Weighted average exercise price	$ 9.32	$ 9.34
Deferred financing costs	$ 320,039	$ 349,018
Deferred financing costs related to line-of-credit arrangements	$ 100,000	$ 25,960
Warrants [Member]
Accounting Policies [Line Items]
Common stock issuable upon exercise of outstanding warrants	2,040,365
Exercise price of warrants	$ 3.44
Restricted Stock Units [Member]
Accounting Policies [Line Items]
Unvested restricted shares	1,271,276	752,008

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted EPS) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Summary Of Significant Accounting Policies [Abstract]
Numerator for basic EPS	$ (2,274,301)	$ (3,135,581)
Numerator for diluted EPS	$ (2,274,301)	$ (3,135,581)
Denominator for basic EPS-weighted average shares	21,611,612	20,742,932
Denominator for diluted EPS-weighted average shares	21,611,612	20,742,932
Basic EPS	$ (0.11)	$ (0.15)
Diluted EPS	$ (0.11)	$ (0.15)

Inventories (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Inventories [Abstract]
Raw materials	$ 2,354,810	$ 2,065,676
Work in process	427,952	24,758
Finished goods	1,702,100	2,433,819
Reserve for obsolescence	(38,499)	(19,971)
Total inventory	$ 4,446,363	$ 4,504,282

Prepaid Expenses And Other Current Assets (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 675,820	$ 454,822
Deferred financing costs	100,000	25,960
Deposits	312,713	136,583
Deferred cost of revenue	94,439	82,987
Total prepaid expenses and other assets	1,182,972	700,352
Less: Noncurrent prepaid expenses and other assets	(32,341)	(31,693)
Total current prepaid expenses and other assets	$ 1,150,631	$ 668,659

Property And Equipment (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 11,120,416	$ 11,120,416
Less: Accumulated depreciation	(10,150,489)	(10,053,095)
Net property and equipment	969,927	1,067,321
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	8,496,636	8,496,636
Equipment Held For Lease [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	303,412	303,412
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,320,368	$ 2,320,368

Intangible Assets (Details)	Mar. 31, 2016 USD ($)
Intangible Assets [Abstract]
Total intangible assets	$ 3,221,069
Accumulated amortization	$ 2,635,010

Accrued Liabilities (Details)	3 Months Ended
Accrued Liabilities (Details)	Mar. 31, 2016 USD ($) ft²	Dec. 31, 2015 USD ($) ft²	Sep. 30, 2013 USD ($) ft²	Dec. 31, 2014 USD ($)
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,266,158	$ 3,053,012
Accrued rent	1,263,383	1,361,379
Accrued licenses and maintenance fees	660,781	666,373
Accrued interest	493,876	494,703
Accrued warranties	302,362	316,835		$ 364,548
Accrued taxes	335,102	324,226
Other	194,166	117,465
Total accrued liabilities	5,515,828	6,333,993
Less: Long term accrued liabilities	(270,433)	(275,603)
Total current accrued liabilities	$ 5,245,395	$ 6,058,390
Square feet of office leased space \| ft²	52,000	3,152
Square feet of demonstration and assembly leased space \| ft²	12,000
Square feet of terminated unimproved leased space \| ft²			13,000
Accrued lease termination costs			$ 515,138
Accrued lease termination costs remaining	$ 258,995
Sublease expiration date	Dec. 31, 2018

Deferred Revenue (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 8,409,175	$ 9,455,133
Less: Long-term deferred revenue	(1,782,155)	(2,009,198)
Total current deferred revenue	6,627,020	7,445,935
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	455,314	366,388
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	1,050,000	2,505,000
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 6,903,861	$ 6,583,745

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References + Details

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities (Revolving Line Of Credit) (Narrative) (Details)	3 Months Ended
	Mar. 31, 2016 USD ($)	May 10, 2016 USD ($)	Dec. 31, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)
Line of Credit Facility [Line Items]
Cash and cash equivalents	$ 1,602,951		$ 5,593,582	$ 4,438,533	$ 7,270,301
Total liquidity	6,500,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 10,000,000
Line of credit maturity date	Mar. 31, 2018
Line of credit facility, amount outstanding	$ 0
Line of credit facility, current borrowing capacity	$ 4,900,000
Subsequent Event [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Minimum tangible net worth requirement, period one		$ (24,000,000)
Minimum tangible net worth requirement, period two		$ (24,500,000)
Subsequent Event [Member] \| Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Liquidity ratio		1.50

Long-Term Debt And Credit Facilities (Healthcare Royalty Partners Debt) (Narrative) (Details) - Healthcare Royalty Partners Debt [Member] - USD ($) $ in Millions			1 Months Ended	3 Months Ended
	Jan. 31, 2013	Aug. 08, 2012	Nov. 30, 2011	Mar. 31, 2016
Debt Instrument [Line Items]
Amount borrowed	$ 2.5	$ 2.5	$ 15.0
Additional amount which may be borrowed			$ 5.0
Percentage of royalties entitled to receive			100.00%
Maturity date				Dec. 31, 2018
Annual interest rate			16.00%

Long-Term Debt And Credit Facilities (Schedule Of Debt Outstanding) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Total long term debt	$ 18,078,308	$ 18,080,159
Carrying Amount [Member]
Debt Instrument [Line Items]
Total debt	18,078,308	18,080,159
Less current maturities
Total long term debt	18,078,308	18,080,159
Estimated Fair Value [Member]
Debt Instrument [Line Items]
Total debt	18,398,347	18,429,177
Less current maturities
Total long term debt	$ 18,398,347	$ 18,429,177

Stockholders' Equity (Narrative) (Details)			1 Months Ended	3 Months Ended
Stockholders' Equity (Narrative) (Details)	Jun. 10, 2014 shares	Jun. 05, 2013 shares	May 31, 2014 USD ($)	Mar. 31, 2016 USD ($) item shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Votes per share \| item				1
Dividends declared				$ 0
Dividends paid				$ 0
2012 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares authorized for issuance under the Plan \| shares	1,000,000	1,000,000
Stock award plans \| shares				46,051
Total compensation cost not yet recognized				$ 2,300,000
Estimated forfeitures				$ 700,000
Weighted average amortization period of total compensation cost not yet recognized				4 years
September 9, 2015 Warrants Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common shares exercised upon conversion of warrants \| shares				267,256
Gross proceeds from stock warrants exercised				$ 293,982
Sales Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross sales price			$ 18,000,000
Commission percentage of gross proceeds			3.00%
Gross proceeds from common stock sold				0
Remaining common stock available				$ 13,800,000

Stockholders' Equity (Summary Of Option And Stock Appreciation Rights Activity) (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2015	706,494
Number of Options/SARs, Granted
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(11,377)
Number of Options/SARs, Outstanding, March 31, 2016	695,117	706,494
Weighted Average Exercise Price per Share, Outstanding, December 31, 2015	$ 9.34
Weighted Average Exercise Price per Share, Granted
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	9.98
Weighted Average Exercise Price per Share, Outstanding, March 31, 2016	9.32	$ 9.34
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit		1.45
Range of Exercise Prices, Upper Limit		$ 116.40
$1.74 - $36.20 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit	1.74
Range of Exercise Prices, Upper Limit	36.20
$1.45 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Prices, Lower Limit	1.45
Range of Exercise Prices, Upper Limit	$ 116.40

Stockholders' Equity (Summary Of Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	3 Months Ended
	Mar. 31, 2016 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, December 31, 2015 \| shares	752,008
Number of Restricted Stock Units, Granted \| shares	700,600
Number of Restricted Stock Units, Vested \| shares	(175,100)
Number of Restricted Stock Units, Forfeited \| shares	(6,232)
Number of Restricted Stock Units, Outstanding, March 31, 2016 \| shares	1,271,276
Weighted Average Grant Date Fair Value per Unit, Outstanding, December 31, 2015 \| $ / shares	$ 2.63
Weighted Average Grant Date Fair Value per Unit, Granted \| $ / shares	0.78
Weighted Average Grant Date Fair Value per Unit, Vested \| $ / shares	3.00
Weighted Average Grant Date Fair Value per Unit, Forfeited \| $ / shares	2.73
Weighted Average Grant Date Fair Value per Unit, Outstanding, March 31, 2016 \| $ / shares	$ 1.56

Fair Value Measurements (Narrative) (Details) - USD ($)	3 Months Ended
Fair Value Measurements (Narrative) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Cash equivalents invested in money market funds	$ 347,821	$ 524,083
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Cash equivalents invested in money market funds	$ 347,821	$ 524,083
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant expiration date	May 01, 2018
Volatility rate	113.14%
Risk-free interest rate	0.73%
Closing stock price	$ 1.10
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued August 2013 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Warrant expiration date	Nov. 01, 2018
Volatility rate	110.74%
Risk-free interest rate	0.87%
Closing stock price	$ 1.10

Fair Value Measurements (Assets And Liabilities Measured At Fair Value On Recurring Basis By Level) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 347,821	$ 524,083
Total assets at fair value	347,821	524,083
Warrants issued	762,836	794,130
Total liabilities at fair value	762,836	794,130
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	237,650	143,681
Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	525,186	650,449
Quoted Prices In Active Markets For Identical Instruments (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	347,821	524,083
Total assets at fair value	347,821	524,083
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Total assets at fair value
Total liabilities at fair value
Significant Other Observable Inputs (Level 2) [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Other Observable Inputs (Level 2) [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities at fair value	762,836	794,130
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	237,650	143,681
Significant Unobservable Inputs (Level 3) [Member] \| Warrants Issued August 2013 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants issued	$ 525,186	$ 650,449

Fair Value Measurements (Summary Of Changes In Fair Value Of Level 3 Financial Liabilities) (Details)	3 Months Ended
	Mar. 31, 2016 USD ($)
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	$ 794,130
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	(31,294)
Liabilities, Balance at end of period	762,836
Warrants Issued May 10, 2012 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	143,681
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	93,969
Liabilities, Balance at end of period	237,650
Warrants Issued August 2013 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities, Balance at beginning of period	650,449
Liabilities, Issues
Liabilities, Settlements
Liabilities, Revaluation	(125,263)
Liabilities, Balance at end of period	$ 525,186

Product Warranty Provisions (Details) - USD ($)	3 Months Ended	12 Months Ended
Product Warranty Provisions (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Product Warranty Provisions [Abstract]
Standard product warranty, coverage term	1 year
Warranty accrual, beginning of the fiscal period	$ 316,835	$ 364,548
Accrual adjustment for product warranty	55,262	171,384
Payments made	(69,735)	(219,097)
Warranty accrual, end of the fiscal period	$ 302,362	$ 316,835

Subsequent Events (Details) - Subsequent Event [Member] - Revolving Credit Facility [Member] $ in Millions	May 10, 2016 USD ($)
Subsequent Event [Line Items]
Minimum tangible net worth requirement, period one	$ (24.0)
Minimum tangible net worth requirement, period two	$ (24.5)